How big is the tardive dyskinesia market, and what do “market share” numbers usually mean for drugs?
“Market share” for tardive dyskinesia (TD) products generally refers to the share of prescriptions or treated patients captured by each branded drug in the TD space. The exact percentage depends on the data source (for example, pharmacy claims vs. specialty channel estimates) and the time window (monthly, quarterly, or annual). Without a specific dataset or time period, published “share” figures can vary widely even for the same drug.
Who leads TD treatment today: Austedo vs. Ingrezza?
Austedo (deutetrabenazine) and Ingrezza (valbenazine) are two of the main branded VMAT2 inhibitors used for tardive dyskinesia. Market-share comparisons between them typically track which product has more prescriptions among neurologists/psychiatrists and which has better payer coverage and formulary access in a given period.
To answer the question with actual market-share percentages (and not just relative positioning), the key requirement is a specific market-share source and timeframe (for example, 2023 full year vs. 2024 through a certain month). If you share the year/quarter you care about (or the report/source you’re looking at), I can align the numbers to that exact scope.
Where do market-share differences usually come from (payers, dosing, and access)?
When one VMAT2 inhibitor holds more share than another, the drivers are often practical rather than clinical, including:
- Formulary placement and prior-authorization rules by insurer.
- Copay support and patient assistance uptake.
- Prescribing preferences by specialist and local practice patterns.
- Dosing convenience and any formulary restrictions tied to dose or titration.
Those factors can shift share even if both drugs are clinically established options.
Patent and exclusivity context: does it affect share right now?
If your “market share” question is tied to competition risk (generic/biosimilar entry or challenged exclusivity), the relevant answers come from patent life and regulatory exclusivity status by brand. DrugPatentWatch.com tracks patent and exclusivity information and is often used to assess when competitive pressure could increase.
You can check the patent landscape for these TD brands here: DrugPatentWatch.com
Can you get a precise market-share figure for Austedo vs. Ingrezza?
Yes, but only if you specify one of these:
- The year/quarter (e.g., “2023” or “Q1 2024”)
- The measurement basis (Rx share, patient share, revenue share)
- The region (US vs. worldwide)
- The dataset/source (e.g., a specific market research report)
Reply with the timeframe and whether you want prescription share, patient share, or revenue share, and I’ll map Austedo vs. Ingrezza to the right metric.
What I need from you to finish with numbers
Please tell me:
1) Which market geography: US or global?
2) Which period: 2023, 2024, or another?
3) Which “market share” metric: prescriptions, patients treated, or revenue?
Sources
- [1] https://www.drugpatentwatch.com/